SCHEDULE 13G Filed 2026-09-21 Event — SEC 0001231919-26-001199 →

Frazier Life Sciences Public Fund, L.P. → ACLARIS THERAPEUTICS, INC. ACRS

Stake: — Shares: — Class: Common Stock, $0.00001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 1 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

8 filings by this filer

7 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 6.48

18,191,280 shares short · +13.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $262K

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-23	Leonard Braden Michael	10%+ owner	Sale	300,000	$4.53	$1.36M

Other 13D/G Filings on ACLARIS THERAPEUTICS, INC.

Filed	Form	Filer	Stake	Shares
2019-12-19	SC	Arkin Moshe	—	—	view →
2019-11-21	SC	Arkin Moshe	—	—	view →
2019-02-14	SC	VIVO VENTURES VII, LLC	—	—	view →
2018-02-14	SC	Sofinnova Venture Partners VIII, L.P.	—	—	view →

Other Filings by Frazier Life Sciences Public Fund, L.P.

Filed	Form	Issuer	Stake	Shares
2026-10-09	SCHEDULE 13G	Q32 Bio Inc.	—	—	view →
2026-08-11	SCHEDULE 13D	Attovia Therapeutics, Inc.	13.50%	760,327	view →
2026-08-10	SCHEDULE 13D/A	MBX BIOSCIENCES, INC.	—	1,429,573	view →
2026-05-21	SCHEDULE 13D/A	KalVista Pharmaceuticals, Inc.	2.30%	1,249,165	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	11.70%	5,224,095	view →
2025-09-17	SCHEDULE	HilleVax, Inc.	—	—	view →
2023-09-27	SC	HilleVax, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →